… ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB LEIDEN, … 2018 Conference ProQR will deliver a presentation on the Axiomer ® RNA editing technology during the TIDES: …
… ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology Key updates ProQR … (Nasdaq:PRQR), today announced that a presentation titled “Axiomer ® Technology: Therapeutic Oligonucleotides for …
… Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology Key Updates Dr. Peter … in advancing the company’s novel and proprietary Axiomer ® RNA editing technology. The board now consists of …
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will
… During the event, ProQR will highlight its proprietary Axiomer™ ADAR-mediated RNA editing platform, along with … diseases to prevent the need for transplantation About Axiomer ™ ProQR is pioneering a next-generation RNA base …
Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from Cohort 1 expected by year-end, and target engagemen
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will p
… momentum toward the clinic Accelerated development of Axiomer™ for CNS applications via new research partnership … on RNA editing, ProQR made important progress with Axiomer, our ADAR-mediated RNA editing technology platform,” …
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief